Activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor are associated with improved survival in gefitinib-treated chemorefractory lung adenocarcinomas. (Q40382332)
Jump to navigation
Jump to search
scientific article published on August 2005
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor are associated with improved survival in gefitinib-treated chemorefractory lung adenocarcinomas. |
scientific article published on August 2005 |
Statements
Activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor are associated with improved survival in gefitinib-treated chemorefractory lung adenocarcinomas (English)
Miguel Taron
Yukito Ichinose
Bartomeu Massuti
Jose Luis Mate
Christian Manegold
Mayumi Ono
Cristina Queralt
Thierry Jahan
Jose Javier Sanchez
Maria Sanchez-Ronco
Victor Hsue
David Jablons
Jose Miguel Sanchez
Teresa Moran